RBC Capital Markets initiated coverage on Grail Inc. with a Sector Perform rating and an $84 price target, highlighting the substantial market opportunity for its multi-cancer early detection test, Galleri. The upcoming FDA advisory committee meeting for Galleri on September 23rd is identified as a key near-term catalyst, with RBC expecting potential FDA approval in late 2026/early 2027.
RBC Capital Markets initiating coverage on Grail Inc. with a Sector Perform rating and an $84 price target is a significant event for the company, providing institutional validation and a public valuation benchmark. The analyst's positive view on the market opportunity for Galleri and the upcoming FDA adcom are key short-term catalysts that could drive stock movement. However, concerns about cash burn and reimbursement challenges temper the immediate upside, leading to a 'Sector Perform' rather than 'Outperform' rating. Long-term implications hinge on successful FDA approval and favorable reimbursement policies, which would unlock the massive addressable market for multi-cancer early detection tests.